We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$115M
Cap. Flow %
6.95%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$23.8M
2
VTRS icon
Viatris
VTRS
+$14.8M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
5
NVRO
NEVRO CORP.
NVRO
+$12.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.4M
2
BLUE
bluebird bio
BLUE
+$16.3M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12.1M
4
QURE icon
uniQure
QURE
+$11.1M
5
RLYP
RELYPSA INC COM
RLYP
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Consumer Staples 0.52%
3 Financials 0.09%
4 Technology 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
51
Insmed
INSM
$27.1B
$6.98M 0.42%
285,812
-300,000
-51% -$6.81M
VBIV
52
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$6.81M 0.41%
87,012
– –
ALDX icon
53
Aldeyra Therapeutics
ALDX
$93.5M
$6.75M 0.41%
869,800
+512,800
+144% +$4.42M
CLLS
54
Cellectis
CLLS
$344M
$6.55M 0.39%
181,500
+180,000
+12,000% +$6.32M
ELDN icon
55
Eledon Pharmaceuticals
ELDN
$282M
$6.46M 0.39%
2,996
+167
+6% +$323K
IMUX icon
56
PUT
Immunic
IMUX
$224M
$6.33M 0.38%
+750
New +$7.16M
LJPC
57
DELISTED
La Jolla Pharmaceutical Company
LJPC
$6.2M 0.37%
252,915
– –
ASXC
58
DELISTED
Asensus Surgical, Inc.
ASXC
$6.13M 0.37%
157,233
+55,028
+54% +$2.54M
IRWD icon
59
Ironwood Pharmaceuticals
IRWD
$725M
$5.95M 0.36%
+589,358
New +$6.85M
FPRX
60
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5.57M 0.34%
224,129
– –
ILMN icon
61
Illumina
ILMN
$34B
$5.46M 0.33%
25,700
+22,761
+774% +$4.45M
PTLA
62
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$5.06M 0.3%
111,103
-243,897
-69% -$9.81M
ARDX icon
63
Ardelyx
ARDX
$976M
$5.05M 0.3%
315,955
– –
TARA icon
64
Protara Therapeutics
TARA
$235M
$4.91M 0.3%
6,875
– –
ELGX
65
DELISTED
Endologix Inc
ELGX
$4.88M 0.29%
31,800
-24,700
-44% -$4.08M
TTPH
66
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$4.74M 0.29%
5,000
– –
NERV icon
67
Minerva Neurosciences
NERV
$239M
$4.7M 0.28%
101,317
– –
AGTC
68
DELISTED
Applied Genetic Technologies Corporation
AGTC
$4.62M 0.28%
300,922
-300
-0.1% -$5.75K
HCA icon
69
HCA Healthcare
HCA
$92.8B
$4.59M 0.28%
50,563
+563
+1% +$45.1K
THOR
70
CALL
DELISTED
THORATEC CORPORATION
THOR
$4.46M 0.27%
100,000
– –
CDTX
71
DELISTED
Cidara Therapeutics
CDTX
$4.21M 0.25%
+15,000
New +$4.61M
NKTR icon
72
Nektar Therapeutics
NKTR
$2.56B
$4.19M 0.25%
+22,333
New +$3.84M
RPTP
73
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$4.17M 0.25%
264,204
+4
+0% +$49
CYAD
74
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$3.9M 0.24%
+75,000
New +$4.03M
SIOX
75
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.87M 0.23%
+23,750
New +$4.03M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $115M of net new capital in Q2 2015, opening 55 new positions and adding to 41 existing holdings. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.4M trimmed.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.